Jungheon Varenicline Salicylate Tablet 1 Milligram

Adult dose

1. Usual dosage in adults Patients should set a quit date and begin taking this medicine 1 week before that date. Alternatively, they may start trying to quit between day 8 and day 35 after starting this medicine. This medicine should be taken after meals with plenty of water. The recommended dosage of this medicine is as follows: after dose titration over 1 week, take 1 mg twice daily. Days 1 – 3 0.5 mg once daily Days 4 – 7 0.5 mg twice daily Day 8 – end of treatment 1 mg twice daily Patients who cannot tolerate the adverse reactions of this medicine may temporarily or permanently reduce the dose. The treatment period is 12 weeks. For patients who successfully quit smoking with the first 12 weeks of treatment, it is recommended that this medicine be continued for an additional 12 weeks to increase the likelihood of long-term abstinence. For patients who cannot or do not wish to stop smoking abruptly, gradual smoking cessation while taking this medicine may be considered. Reduce smoking by 50% from the pretreatment level within the first 4 weeks after starting this medicine, and by an additional 50% over the next 4 weeks; continue to reduce smoking so that complete cessation is achieved by 12 weeks. Continue this medicine for an additional 12 weeks, for a total treatment period of 24 weeks. Patients who fail to quit smoking after the first 12 weeks of treatment, or who resume smoking after treatment, should review the reasons for failure and try again. However, there are no data demonstrating the efficacy of an additional 12 weeks of treatment in patients who failed to quit during the initial 12 weeks or resumed smoking after treatment. 2. Patients with renal impairment No dose adjustment is necessary in patients with mild (estimated creatinine clearance > 50 ml/min and ≤ 80 ml/min) to moderate (estimated creatinine clearance ≥ 30 ml/min and ≤ 50 ml/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease receiving hemodialysis, if well tolerated, a maximum dose of 0.5 mg once daily may be administered. 3. Elderly patients and patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. In elderly patients, renal function is more likely to be reduced, so care should be taken when selecting the dose; monitoring renal function may be useful.

Child dose

Administration is not recommended in patients under 18 years of age.

This medication is a drug that helps with smoking cessation and may affect mental health during use, so caution is needed. Serious psychiatric symptoms such as depression, anxiety, aggression, hallucinations, and suicidal thoughts may occur during treatment with this drug. Therefore, patients with a history of psychiatric disorders must consult with a physician, and if symptoms occur, they should stop taking the medication immediately and consult healthcare professionals. In cases of pregnancy or breastfeeding, careful consideration should be given to the potential effects of this medication on the fetus or infant. Common side effects such as nausea, headaches, insomnia, and abnormal dreams may occur early in treatment, but they are mostly mild and improve over time. Patients with cardiovascular disease should follow their physician's instructions as heart-related symptoms may worsen with this medication. Caution is also required when engaging in hazardous activities such as driving or operating machinery, as this medication may cause drowsiness or decreased concentration. Additionally, taking this medication with alcohol may exacerbate side effects, so it is advisable to avoid alcohol consumption as much as possible. Its safety and efficacy have not been established for children and adolescents under 18 years of age, hence its use is not recommended. Elderly patients may require dose adjustments due to decreased renal function, and regular monitoring of renal function is necessary. In case of overdose, there is no specific antidote, thus appropriate treatment should be administered according to symptoms, and the medication should be kept out of reach of children.

• Suicidal ideation
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• mood changes
• psychosis
• aggressive behavior
• hallucinations

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is recommended to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance

Pale blue, biconvex, rectangular film-coated tablet

Package unit

28 tablets (14 tablets/BlisterX2)